Venomaid's rapid test aims to find the right snake bite treatment

Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom ca...

Swedish life science is growing – but capital is not keeping up

The number of employees and companies in Swedish life science is increasing and the sector is more equal than many other sectors. But investments in unlisted co...

The FDA’s new transparency policy (Part 3)

As transparency and consistency become increasingly emphasized by the FDA, medical device manufacturers must approach their submissions with both thoroughness a...

The vaccine has saved 94 million lives – but measles is spreading again

A disease we once believed belonged to the past is now resurging in both Europe and the United States. In the shadow of growing skepticism and declining vaccina...

Del 3 av Advance serien: Design

Ta reda på hur du kan omvandla en audit till en konkret lösning. Spirax Sarcos designfas ger dig allt du behöver för att implementera ett optimerat och framtids...

New version of ISO 10993-1: the core standard for the biological evaluation of medical devices

ISO 10993-1, the core standard for the biological evaluation of medical devices, has been under revision over the past few years. A Final Draft International St...

Gene therapy restored hearing in children with congenital deafness

Eleven out of twelve children with congenital deafness showed improvements in a study testing Regeneron’s gene therapy for hereditary hearing loss. The U.S. com...

3 000 ska bort från Australiens största läkemedelsbolag

Det australiensiska läkemedelsjätten CSL genomför sparåtgärder. I planen ingår bland annat att knoppa av bolagets vaccinenhet och minska arbetsstyrkan med 3 000 medarbetare.

How the Nobel discovery is used in drug development

Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how t...

A cluster contribution to European life science innovation and competitiveness?

Pulsen på patientförbunden del 3: Reumatism

”Våra forskarkollegor har en vision om att reumatiska sjukdomar ska kunna förebyggas”, skriver Reumatikerförbundets ordförande Lotta Håkansson.

ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

Digitalt lyft för Life Science Sweden och resten av Nordiske Medier

Life Science Sweden är en av många branschtidningar som ges ut av B2B-förlaget Nordiske Medier, som nu kan erbjuda alla läsare en mer modern och användarvänlig plattform.

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

Investment CEO: “The Nordics are outstanding in creating successful medtech companies”

Since the beginning of last month, Susanna Francke Rodau has been a partner and the new CEO of Segulah Medical Acceleration, which invests in medical technology...

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes

An increasing number of people are falling ill with TBE – “Much more research is needed”

Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Över...

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.

3 avgörande faktorer vid valet av nytt affärssystem

Att investera i ett ERP-system innebär att navigera genom en mängd frågor och alternativ. En av de största utmaningarna är att hitta rätt lösning för ert företa...

Crispr-bolag pausar studier efter rapport om allvarliga biverkningar

En allvarlig leverpåverkan hos en patient gör att amerikanska Intellia Therapeutics nu stoppar behandling och rekrytering i fas 3-studier med företagets genterapi.

The US is leaving the WHO

The newly installed US President, Donald Trump, has issued an executive order for the US to leave the World Health Organization, WHO.

Framsteg för Novartis kandidat mot Sjögrens sjukdom

Novartis har presenterat fas 3-data för den monoklonala antikroppen ianalumab, som visade en statistiskt signifikant minskning av sjukdomsaktivitet hos patiente...

Trender inom life science 2025 – Del 3 ekonomin

Kommande patentutgångar driver läkemedelsbolagen att förvärva under 2025. I Sverige kan vi vara på väg mot ljusare tider och färre konkurser. Del 3 i serien med...